ClinicalTrials.gg
CompletedNCT02894385Updated Jan 7, 2019

Effect of Hepatic and Renal Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1841788 (ODM-201)

A Phase 1 interventional study of BAY1841788 in Pharmacokinetics, Hepatic Insufficiency and Renal Insufficiency, sponsored by Bayer. Completed at 2 sites in Germany. Open to male participants aged 45 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-07.

Sponsored by Bayer · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Non-randomized
Ages
45 Years to 79 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Hepatic Insufficiency with a site in Germany — none open to participants now, none under way, none of them phase 3. Hepatic Insufficiency · Germany.

Enrollment
7th of 12
29 · median 30
Started
2016
the only one that year
Phase 1
9 of 14
none open now
Registered
9th of 14
by date
Lead sponsor
2 of 14
Bayer

Among the 14 studies in Hepatic Insufficiency with a site in Germany, this one is the 7th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2016, is one of 9 in phase 1, and was the 9th registered.

Hepatic Insufficiency

113 studies on the registry are indexed under Hepatic Insufficiency; 15 are open to participants now.

Browse Hepatic Insufficiency studies →

Open to participants now

None of the 14 studies in Hepatic Insufficiency with a site in Germany is open now. The open studies under Hepatic Insufficiency, anywhere →

Who these studies take

Of the 9 Hepatic Insufficiency studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 45 Years to 79 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Hepatic Insufficiency with a site in Germany as a file.
02

Study summary

Evaluate the potential effect of hepatic or renal impairment on the pharmacokinetics, safety and tolerability of BAY 1841788 (ODM-201).

Read the detailed description

The study was closed after Part 1 because additional investigation in volunteers with moderate renal impairment in Part 2 was not deemed to be ethically or scientifically justified.

03

Conditions studied

  • Pharmacokinetics
  • Hepatic Insufficiency
  • Renal Insufficiency
04

Who can participate

Ages eligible
45 Years to 79 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All subjects

    -- Male and white subjects between 45 and 79 years of age with a between 18 to 34 kg/m*2 (both inclusive).

  • Patients with moderate hepatic impairment (Part 1)

    -- Patients with documented liver cirrhosis confirmed by histopathology, e.g., previous liver , laparoscopy, ultrasound, or fibroscan and with moderate hepatic impairment (defined as class B).

  • Patients with severe renal impairment (Part 1)

    -- Patients with severe renal impairment with an estimated 15-29 mL/min/1.73 m*2, who are not on dialysis and are not expected to start dialysis in the next 3 months (Stage 4).

  • Healthy subjects

    -- Healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring and with estimated glomerular filtration rate >90 mL/min (according to Modified Diet of Renal Disease equation).

  • Patients with moderate renal impairment (Part 2)

    -- Patients with moderate renal impairment with an estimated glomerular filtration rate 30-59 mL/min/1.73 m*2 (Stage 3).

  • Patients with mild renal impairment (Part 2)

    -- Patients with mild renal impairment with an estimated glomerular filtration rate (eGFR) 60-79 mL/min/1.73 m*2 (Stage 2).

  • Patients with mild hepatic impairment (Part 2)

    • Patients with documented liver cirrhosis confirmed by histopathology, e.g., previous liver biopsy, laparoscopy, ultrasound, or fibroscan.
    • Patients with mild hepatic impairment (defined as Child Pugh class A).

Exclusion criteria

Exclusion Criteria:

  • Severe cerebrovascular or cardiac disorders, e.g., myocardial infarction less than 6 months prior to dosing, congestive heart failure of (NYHA) grade III or IV.
  • Subjects with percutaneous transluminal coronary angioplasty or coronary artery bypass graft less than 6 months prior to study drug administration.
  • Strong cytochrome P450 (CYP) 3A4 inhibitors or strong inducers within 28 days or 5 drug half-lives (if drug half-life in patients is known), before start of study treatment.
  • Known BCRP (breast cancer resistant protein) and OATP (organic anion-transporting polypeptide) substrates not specifically mentioned in the protocol within 28 days or 5 drug half-lives (if drug half-life in patients is known), before start of study treatment.
  • Smoking more than 20 cigarettes daily.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Part 1 - Subjects with severe renal impairment

    Subjects with severe renal impairment received a single oral dose of darolutamide 600 mg (2 x 300 mg tablets).

    Drug: BAY1841788

  • Experimental
    Part 1 - Subjects with moderate hepatic impairment

    Subjects with moderate hepatic impairment received a single oral dose of darolutamide 600 mg (2 x 300 mg tablets).

    Drug: BAY1841788

  • Experimental
    Part 1 - Healthy subjects

    Healthy subjects received a single oral dose of darolutamide 600 mg (2 x 300 mg tablets).

    Drug: BAY1841788

Interventions

  • 600 mg single dose, administered as 2 x 300 mg tablets on Day 00.

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve of darolutamide from time zero to 48 hours (AUC(0-48)) in plasma

    Time frame: Pre-dose up to 48 h post dose

  2. Maximum drug concentration (Cmax) of darolutamide in plasma

    Time frame: Pre-dose up to 48 h post dose

Secondary outcomes

  1. Area under the concentration-time curve of darolutamide's diastereomer ((S,R)-darolutamide) from time zero to 48 hours (AUC(0-48)) in plasma

    Time frame: Pre-dose up to 48 h post dose

  2. Maximum drug concentration (Cmax) of darolutamide's diastereomer ((S,R)-darolutamide) in plasma

    Time frame: Pre-dose up to 48 h post dose

  3. Area under the concentration-time curve of darolutamide's diastereomer ((S,S)-darolutamide) from time zero to 48 hours (AUC(0-48)) in plasma

    Time frame: Pre-dose up to 48 h post dose

  4. Maximum drug concentration (Cmax) of darolutamide's diastereomer ((S,S)-darolutamide) in plasma

    Time frame: Pre-dose up to 48 h post dose

  5. Area under the concentration-time curve of darolutamide's major metabolite (keto-darolutamide) from time zero to 48 hours (AUC(0-48)) in plasma

    Time frame: Pre-dose up to 48 h post dose

  6. Maximum drug concentration (Cmax) of darolutamide's major metabolite (keto-darolutamide) in plasma

    Time frame: Pre-dose up to 48 h post dose

  7. Number of subjects with study drug-related treatment-emergent adverse events (TEAEs)

    Time frame: From first application of study medication up to 30 days after end of treatment with study medication.

07

Study locations

2 sites
  • Kiel, Schleswig-Holstein 24105, Germany
  • Lübeck, 23538, Germany
08

References and documents

Publications

  • Zurth C, Nykanen P, Wilkinson G, Taavitsainen P, Vuorela A, Huang F, Reschke S, Koskinen M. Clinical Pharmacokinetics of the Androgen Receptor Inhibitor Darolutamide in Healthy Subjects and Patients with Hepatic or Renal Impairment. Clin Pharmacokinet. 2022 Apr;61(4):565-575. doi: 10.1007/s40262-021-01078-y. Epub 2021 Dec 6. PubMed 34866168 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Apr 2017, 6 months.

Of 38 industry-sponsored phase 1 interventional studies under Hepatic Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 17. This study's 6 months is below that.

Counting every sponsor, half of 41 studies reached it within 8 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2016
First posted
Sep 9, 2016
StartActual
Sep 13, 2016
Primary completionActual
Apr 10, 2017
CompletionActual
Dec 15, 2017
Last update
Jan 7, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02894385
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Sep 9, 2016
Start date
Sep 13, 2016
Primary completion
Apr 10, 2017
Completion
Dec 15, 2017
Last update
Jan 7, 2019

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Darolutamide

Start the discussion